News >

FDA Approves Fostamatinib for Chronic ITP

Silas Inman @silasinman
Published: Tuesday, Apr 17, 2018

Dr James Bussel
James Bussel, MD
The FDA has approved the SYK inhibitor fostamatinib (Tavalisse) as a second-line treatment for patients with chronic immune thrombocytopenia (ITP) following insufficient response to a previous therapy, based on findings from 2 randomized trials and 1 open-label extension study.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: New Frontiers in the Management of GvHD: Uncovering the Latest Advances to Improve Post-Transplant CareMay 31, 20191.5
Advances In™ Supportive Care: An Onco-Nurses Guide to Managing Cancer Treatment-Related ToxicitiesJun 29, 20191.0
Publication Bottom Border
Border Publication